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Summary
Background Systemic sclerosis (SSc) is a connective tissue disorder with excessive
ﬁbrosis of the skin and various internal organs. Although SSc is a heterogeneous
disease, it has been reported that the particular antinuclear antibodies (ANA) are
often indicative of clinical features, disease course and overall severity.
Objective To clarify the association of clinical and prognostic features with serum
ANA in Japanese patients with SSc.
Methods We studied 203 Japanese patients diagnosed with SSc, who visited our
hospital during the period 1983–2005. Six SSc-related ANA were identiﬁed using
indirect immunoﬂuorescence, double immunodiffusion and immunoprecipitation
assays.
Results Patients with SSc were classiﬁed into six ANA-based subgroups and a group
without ANA. As expected, antitopoisomerase I antibody (Ab, n = 64), anti-RNA
polymerases (RNAP) Ab (n = 12) and anti-U3 RNP Ab (n = 5) were associated
with diffuse cutaneous SSc, whereas anticentromere Ab (ACA, n = 75), anti-
Th⁄To Ab (n = 7) and anti-U1 RNP Ab (n = 10) were frequently detected in
patients with limited cutaneous SSc. Clinical features of the ANA-negative group
(n = 10) were heterogeneous. Consistent with previous ﬁndings in Caucasian
and⁄or black African patients, antitopoisomerase I Ab was associated with the
involvement of vascular and pulmonary ﬁbrosis, leading to decreased survival
rate. However, no patients with anti-RNAP Ab developed renal crisis and the
frequency of isolated pulmonary hypertension in patients with ACA, anti-Th⁄To
Ab or anti-U3 RNP Ab was similar to that in other ANA-based subgroups.
Conclusion These results indicate that the clinical relevance of SSc-related ANA in
Japanese patients differs in some aspects from that in Caucasian and⁄or black
African patients.
Systemic sclerosis (SSc) is a connective tissue disorder charac-
terized by microvascular damage and excessive ﬁbrosis of the
skin and various internal organs. There are variations of clini-
cal expression in patients with SSc, ranging from limited cuta-
neous SSc (lSSc), in which skin thickening is relatively
restricted to the ﬁngers and hands, and with less serious in-
ternal organ involvement, to diffuse cutaneous SSc (dSSc), in
which skin lesions are extensive and often rapidly developing,
with earlier and more serious complications.
1 One representa-
tive feature of the immunological abnormalities in patients
with SSc is the presence of antinuclear antibodies (ANA).
More than 90% of patients with SSc are positive for ANA, and
these ANA react to various intracellular components.
2 Several
major ﬁndings with regard to ANA have been reported previ-
ously in patients with SSc. Production of speciﬁc ANA is
exclusive and one patient rarely has two or more SSc-related
speciﬁc ANA.
3 If once ANA have appeared, usually they do
not change into other speciﬁc ANA or disappear during the
disease course.
4 Although the role of ANA in the pathogenesis
of SSc remains unknown and they may not be directly
involved, particular ANA are often indicative of clinical fea-
tures, disease course and overall severity. Therefore, informa-
tion on ANA is a valuable help in diagnosing and evaluating
the prognosis of an individual patient with SSc.
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termed anti-Scl-70)
5 and anticentromere antibody (ACA)
6 are
two representative ANA found in SSc. Other serum ANA asso-
ciated with SSc include anti-U1 ribonucleoprotein (RNP),
7
anti-RNA polymerases I, II and III (anti-RNAP),
8,9 anti-
Th⁄To
10 and anti-U3 RNP (ﬁbrillarin)
11 antibodies. It has
been reported that there are several clinical associations with
these ANA. ACA
12–14 and anti-Th⁄To
15,16 are associated with
lSSc and with a low frequency of severe internal organ
involvement, although some patients with these ANA develop
isolated pulmonary arterial hypertension (PAH). In contrast,
anti-topo I is generally associated with dSSc and a high fre-
quency of pulmonary ﬁbrosis.
17,18 Anti-RNAP is frequently
detected in patients with dSSc and is associated with a higher
proportion of male patients, the onset of disease at a greater
age and a high frequency of renal disease.
8,9 Anti-U1 RNP is
often found in overlap syndrome, especially mixed connective
tissue disease, and is associated with isolated PAH and arthri-
tis.
19 Anti-U3 RNP is generally detected in patients with dSSc
with a low frequency of joint and pulmonary involvement or
with isolated PAH, skeletal muscle involvement and early dis-
ease onset.
20 Approximately 5–10% of patients with SSc are
likely to have no serum ANA. The detailed clinical presenta-
tion in this subgroup remains unclear.
It is well known that ethnic and genetic background affect
frequencies of ANA and clinical features in patients with
SSc.
21 Most reports have described demographic and clinical
features in Caucasian and⁄or black African patients with SSc
and relatively small studies have been performed on Japanese
patients with SSc. In this study, we attempted to identify a
correlation between SSc-related ANA and clinical features and
prognosis in 203 Japanese patients with SSc.
Patients and methods
Patients and serum samples
We analysed serum samples from 203 Japanese patients with
SSc (173 women and 30 men). All patients fulﬁlled the crite-
ria for classiﬁcation of deﬁnite SSc proposed by the American
College of Rheumatology.
22 The mean age of the patients was
46 ± 15 years and the disease duration was 6Æ6±8 Æ3 years.
The disease duration was calculated from the onset of the ﬁrst
clinical event that was a clear manifestation of SSc. At their
ﬁrst visit, 12 patients had been treated with low-dose cortico-
steroid (prednisolone 5–20 mg daily) and 19 patients with
D-penicillamine (100–300 mg daily). None of the patients
with SSc had received other immunosuppressive therapies. The
patients were grouped according to the classiﬁcation system
proposed by LeRoy et al.:
1 112 patients (104 women and eight
men) had lSSc and 91 patients (69 women and 22 men) had
dSSc. Patients with SSc in overlap syndrome, which is mostly
characterized by SSc with systemic lupus erythematosus or
polymyositis, were excluded from this study.
At the most recent observation point, 185 patients were still
alive. The mean follow-up period including 18 deceased
patients was 7Æ1±4 Æ3 years. Seventy-seven patients received
corticosteroid (prednisolone 5–30 mg daily) and seven
received low-dose D-penicillamine (100–300 mg daily)
throughout the follow-up period. One patient received steroid
pulse therapy, followed by oral prednisolone 40 mg daily for
subacute deterioration of interstitial pneumonitis during the
follow-up period. Fresh venous blood samples were centri-
fuged shortly after clot formation. All samples were stored at
)70  C before use.
The protocol was approved by the Kanazawa University
School of Medical Science and Kanazawa University Hospital,
and informed consent was obtained from all study subjects.
Antinuclear antibody analysis
A total of 203 serum samples from Japanese patients with SSc
were analysed for ANA. Indirect immunoﬂuorescence tests
were performed using slides of monolayer HEp-2 cells (Medi-
cal & Biological Laboratories, Nagoya, Japan) as substrate.
8
Ouchterlony double immunodiffusion tests and immuno-
precipitation assays using nonradiolabelled and
35S-methio-
nine-labelled K562 cell extracts
23,24 were also carried out
(Fig. 1a,b). Six well-known SSc-related ANA were deﬁned in
this study as follows. ACA was considered positive if serum
diluted at 1 : 40 produced a characteristic staining pattern on
HEp-2 cells as well as on commercially prepared HeLa cell
chromosomal spreads (Medical & Biological Laboratories).
6
Anti-U1 RNP,
25 anti-Th⁄To
10 and anti-U3 RNP
20 antibodies
were detected by immunoprecipitation using nonradiolabelled
K562 cell extracts. Immunoprecipitated RNA was detected
in 8% urea–polyacrylamide gel electrophoresis (PAGE) from
a cell extract obtained from 3 · 10
6 K562 cells by phenol⁄
chloroform, visualized by silver staining. Anti-RNAP
8 was
detected by immunoprecipitation of proteins detected in
sodium dodecyl sulphate (SDS)-PAGE from a cell extract
obtained from 1 · 10
6 K562 cells radiolabelled with 50 lCi of
35S-methionine. Anti-topo I was considered positive if serum
samples produced precipitin lines with immunological identity
to reference sera on double immunodiffusion, or if it immuno-
precipitated a protein with a molecular weight of ~100 kDa
from
35S-methionine-labelled K562 cell extracts. We deﬁned
sera without the presence of any characteristic staining on
HEp-2 cells using sera diluted to 1 : 40 as negative for ANA.
Clinical assessment
At their ﬁrst visit, complete medical histories were obtained,
and physical examinations and laboratory tests were carried
out for most of the patients, with limited evaluations during
follow-up visits. Serum samples and clinical laboratory data
were obtained at the same time. Skin thickness was scored
according to the modiﬁed Rodnan scoring technique.
26
Brieﬂy, the 17 anatomic areas were rated as 0 (normal skin),
1+ (mild but deﬁnite skin thickening), 2+ (moderate skin
thickening) and 3+ (severe skin thickening), and the modiﬁed
Rodnan total skin thickness score (TSS) was derived by
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Organ system involvement was deﬁned as described previ-
ously:
27,28 lung = bibasilar ﬁbrosis on chest radiography and
high-resolution computed tomography; isolated PAH = clini-
cal evidence of pulmonary hypertension and increased systolic
pulmonary arterial pressure (> 35 mmHg) by echocardiogra-
phy, in the absence of severe pulmonary interstitial ﬁbrosis;
oesophagus = hypomotility shown by barium radiography;
joint = inﬂammatory polyarthralgias or arthritis; heart =
pericarditis, congestive heart failure or arrythmias requiring
treatment; kidney = malignant hypertension and rapidly pro-
gressive renal failure without any other explanation; and
muscle = proximal muscle weakness and elevated serum crea-
tine kinase concentration. Pulmonary function tests, including
vital capacity (VC) and diffusion capacity for carbon monox-
ide (DLco), were also performed. When the DLco and VC
were < 75% and < 80%, respectively, of the predicted normal
values, they were considered abnormal. Two comparisons
were conducted to clarify the associations of SSc-related ANA
with their clinical features. Firstly, we compared the frequen-
cies of SSc-related demographic and clinical features in each
SSc-related ANA-based subgroup with the total group of 203
patients with SSc to make the properties of each SSc-related
ANA clear in the total population of SSc patients. To clarify
the differences in clinical features among the SSc-related ANA-
based subgroups, mutual comparisons were then performed
among six SSc-related ANA-based subgroups and the ANA-
negative SSc patient group.
Statistical analysis
Statistical analysis was performed using Fisher’s exact probabil-
ity test for comparison of frequencies and the Mann–Whitney
U test for comparison of values. The Bonferroni adjustment
was used for multiple comparisons. Cumulative survival rates
were calculated according to life-table methods, and compari-
sons were made using log-rank tests. P <0 Æ05 was considered
statistically signiﬁcant. All data are shown as mean ± SD.
Results
Detection and frequencies of antinuclear antibodies
in Japanese patients with SSc
In sera from 203 Japanese patients with SSc, ACA was present
in 77 (38%), anti-topo I in 67 (33%), anti-RNAP in 12 (6%),
anti-U1 RNP in 11 (5%), anti-Th⁄To in seven (3%), anti-U3
RNP in ﬁve (2%), and no presence of ANA in 10 patients
(5%). Seventeen patients (8%) had ANA which were not iden-
tiﬁed by analysis. Three patients had two kinds of the SSc-
related ANA: two had anti-ACA in addition to anti-topo I and
one had anti-topo I plus anti-U1 RNP. Thus, at least one kind
of SSc-related ANA was present in the sera of 176 patients. In
patients with anti-topo I, 14 were also positive for anti-SS-A
and two for both anti-SS-A and -SS-B. Patients were then
grouped according to ANA speciﬁcity with the following
exception: the three patients with two kinds of SSc-related
ANA were excluded from each ANA-based group (Table 1).
Demographic features
As shown in Table 1, 95% of the ACA-positive patients were
female. This proportion was signiﬁcantly higher than in anti-
RNAP-positive patients (58%, P <0 Æ05). Patients with ACA or
anti-U1-RNP showed a tendency for longer disease duration
(8Æ8–9Æ7 years). In contrast, patients with anti-RNAP, anti-
Th⁄To or anti-U3 RNP, and ANA-negative patients exhibited
shorter disease duration (1Æ9–2Æ6 years). Patients with anti-
topo I had an intermediate disease duration (5Æ1 years). ACA-
positive patients had a signiﬁcantly prolonged mean disease
duration (9Æ7±9 Æ9 years) compared with anti-U3 RNP-
positive (1Æ9±1 Æ8 years) and ANA-negative patients (2Æ2±
2Æ4 years) (P <0 Æ01).
(a) (b)
Fig 1. Immunoprecipitation assay of autoantibodies related to
systemic sclerosis (SSc). (a) Immunoprecipitation of U1
ribonucleoprotein (RNP), Th ⁄To and U3 RNP by sera. K562 cell
extracts were immunoprecipitated with sera and RNA was extracted,
run on 8% urea–polyacrylamide gel electrophoresis (PAGE), visualized
by silver staining. Total RNA, with the 7Æ0, 5Æ8 and 5Æ0 S small
ribosomal RNAs and the tRNA region indicated; lane 1, normal
human serum (NHS); lane 2, anti-U1 RNP-positive sera; lane 3, anti-
Th ⁄To-positive sera; lane 4, anti-U3 RNP-positive sera. (b) Immuno-
precipitation of
35S-methionine-labelled K562 cell extracts was
performed on sera from patients with SSc (lanes 2–6) and NHS,
separated on 10% SDS-PAGE, and analysed by autoradiography.
Molecular weight marker includes protein bands corresponding to
200, 97Æ4, 66, 46 and 30 kDa. Topoisomerase-I (topo-I, lane 2), U1
RNP (lane 3), RNA polymerase I ⁄III, and II (RNAP I ⁄III and II, lane
4), Th ⁄To (lane 5) and U3 RNP (lane 6) proteins are shown by
arrowheads or indicated region.
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When patients with SSc were classiﬁed into the two disease
subsets, the frequency of dSSc was signiﬁcantly higher in
patients with anti-topo I (83%, P <0 Æ01) or anti-RNAP
(100%, P <0 Æ01) compared with the total patients with SSc
(45%, Table 1). In contrast, the percentage of patients with
dSSc was signiﬁcantly lower among the patients with ACA
(5%) than in the total SSc patient group (P <0 Æ01). Patients
with anti-U1 RNP and those with anti-Th⁄To tended to have
lSSc (80% and 86%, respectively), while 80% of anti-U3
RNP-positive patients had dSSc. The frequency of dSSc was
30% in ANA-negative patients. Thus, in general, anti-topo I,
anti-RNAP and anti-U3 RNP were associated with dSSc, while
ACA-, anti-U1 RNP- and anti-Th⁄To-positive patients exhi-
bited lSSc.
Modiﬁed Rodnan total skin thickness score
As skin thickening serves as an effective clinical tool for
assessment of disease severity,
26 direct correlation of each
SSc-related ANA with the modiﬁed Rodnan TSS was assessed
(Table 1). The modiﬁed Rodnan TSS of patients with anti-topo
I (16Æ1±1 0 Æ1) or anti-RNAP (20Æ7±1 0 Æ6) was signiﬁcantly
Table 1 Clinical and laboratory characteristics of 203 Japanese patients with systemic sclerosis (SSc), classiﬁed according to the presence of six
SSc-related antinuclear antibodies (ANA) or absence of ANA
a
Total
(n = 203)
Anti-topo I
(n = 64)
Anti-ACA
(n = 75)
Anti-U1
RNP
(n = 10)
Anti-RNAP
(n = 12)
Anti-Th ⁄To
(n =7 )
Anti-U3
RNP
(n =5 )
Negative
(n = 10)
Sex, female : male
(% female)
173 : 30 (85) 52 : 12 (81) 71 : 4 (95) 7 : 3 (70) 7 : 5 (58) 5 : 2 (71) 5 : 0 (100) 10 : 0 (100)
Age at onset (years),
mean ± SD
46 ± 15 43 ± 18 47 ± 14 42 ± 12 53 ± 16 53 ± 2 45 ± 19 49 ± 7
Duration (years),
mean ± SD
6Æ6±8 Æ35 Æ1±6 Æ69 Æ7±9 Æ98 Æ8±9 Æ82 Æ6±2 Æ82 Æ0±2 Æ21 Æ9±1 Æ82 Æ2±2 Æ4
Disease subset
dSSc : lSSc
(% of dSSc)
91 : 112 (45) 53 : 11 (83)** 4 : 71 (5)** 2 : 8 (20) 12 : 0 (100)** 1 : 6 (14) 4 : 1 (80) 3 : 7 (30)
Modiﬁed Rodnan
TSS
10Æ8±9 Æ41 6 Æ1±1 0 Æ1* 5Æ8±5 Æ7** 5Æ4±5 Æ42 0 Æ7±1 0 Æ6** 7Æ1±9 Æ31 6 Æ6±4 Æ37 Æ1±6 Æ7
Clinical features
Pitting scars 35 58 17 50 25 29 80 10
Contracture of
phalanges
44 50 23 30 83 43 60 30
Diffuse
pigmentation
43 55 21 50 92* 29 60 30
Organ involvement
Lung
Pulmonary
ﬁbrosis
44 84** 7** 30 17 29 0 10
Isolated PAH 14 17 7 20 8 14 0 10
Decreased %VC 22 44* 4* 30 17 29 0 10
Decreased
%DLco
61 78 47 60 58 29 20 70
Oesophagus 65 68 57 80 60 29 100 60
Heart 16 20 12 10 17 14 20 10
Kidney 1 5 0 0 0 0 0 0
Joint 29 31 23 50 50 14 40 20
Muscle 10 13 7 0 17 14 20 20
Laboratory ﬁndings, mean ± SD
ESR (mm h
)1) 22 ± 22 24 ± 21 20 ± 18 40 ± 40* 17 ± 17 18 ± 10 15 ± 8 15 ± 11
CRP (mg dL
)1)0 Æ3±0 Æ70 Æ6±1 Æ10 Æ2±0 Æ40 Æ5±1 Æ00 Æ3±0 Æ30 Æ3±0 Æ20 Æ1±0 Æ10 Æ3±0 Æ5
IgG (mg dL
)1) 1685 ± 590 1735 ± 491 1509 ± 395 2770 ± 1170** 1361 ± 457 1654 ± 448 1957 ± 941 1582 ± 420
aUnless noted otherwise, values are percentages. Three patients with two SSc-related antinuclear antibodies were excluded from each ANA-
based group. Anti-topo I, anti-topoisomerase I; ACA, anticentromere; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-RNAP, anti-RNA
polymerase I, II and III; dSSc, diffuse cutaneous SSc; lSSc, limited cutaneous SSc; TSS, total skin thickness score; PAH, pulmonary arterial
hypertension; VC, vital capacity; DLco, diffusing capacity for carbon monoxide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
*P <0 Æ05 vs. total SSc patients; **P <0 Æ01 vs. total SSc patients.
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(10Æ8±9 Æ4, P <0 Æ05 and P <0 Æ01, respectively). Patients
with anti-U3 RNP had a tendency to have higher modiﬁed
Rodnan TSS (16Æ6±4 Æ3). In contrast, the modiﬁed Rodnan
TSS of ACA-positive patients (5Æ8±5 Æ7) was signiﬁcantly
lower than that of the total SSc population (P <0 Æ05). Patients
with anti-U1 RNP, those with anti-Th⁄To and those without
ANA showed lower TSS (5Æ4±5 Æ4, 7Æ1±9 Æ3 and 7Æ1±6 Æ7,
respectively). These ﬁndings are generally in accordance with
the ﬁndings that most of the patients with anti-topo I, anti-
RNAP or anti-U3 RNP were classiﬁed as dSSc while patients
with ACA, anti-U1 RNP or anti-Th⁄To were generally grouped
into lSSc.
Clinical assessment
We compared the frequencies of SSc-related organ involve-
ment in each SSc-related ANA-based subgroup (Table 1).
Pitting scars were seen more frequently in patients with
anti-topo I, anti-U1 RNP or anti-U3 RNP than in patients with
ACA, anti-RNAP or anti-Th⁄To and those without ANA,
although the difference did not reach statistical signiﬁcance.
Contracture of phalanges was seen frequently in all subgroups,
although it was relatively higher in patients with anti-RNAP
and lower in patients with ACA or anti-U1 RNP and those
without ANA. Diffuse pigmentation was found more fre-
quently in patients with anti-RNAP (92%) than in the total
patients (43%, P <0 Æ05). Patients with anti-topo I or anti-U3
RNP tended to have this symptom, but it was infrequently
found in ACA-positive, Th⁄To-positive and ANA-negative
patients. These ﬁndings suggest that contracture of phalanges
or diffuse pigmentation is generally related to the extent of
skin sclerosis. However, the frequency of pitting scars was not
necessarily associated with the severity of skin sclerosis, as the
scars were infrequent in anti-RNAP-positive patients.
Most organ system involvement and laboratory ﬁndings are
primarily associated with SSc-related ANA, rather than the dis-
ease subsets.
29 Pulmonary ﬁbrosis (84%, P <0 Æ01 vs. total
patients) and decreased %VC (44%, P <0 Æ05 vs. total
patients) were most common in patients with anti-topo I and
most infrequent in patients with ACA (7%, P <0 Æ01 and 4%,
P <0 Æ05 vs. total patients, respectively, Table 1), as previously
shown.
27 Decreased %DLco was commonly seen in patients
with SSc, except for patients with anti-Th⁄To (29%) or anti-
U3 RNP (20%). The frequency of isolated PAH was between
0 and 20% in all subgroups and no signiﬁcant difference was
found. Upper gastrointestinal involvement, which is generally
represented by oesophageal dysfunction, occurred in more
than 50% of patients in all subgroups, except for patients with
anti-Th⁄To (29%). Severe heart and muscle involvement was
infrequent and occurred in 20% or less in all subgroups
without any signiﬁcant association with speciﬁc ANA. Only
three patients experienced renal crisis and all of them had
anti-topo I.
In laboratory ﬁndings, patients with anti-U1 RNP showed
a signiﬁcantly higher erythrocyte sedimentation rate and
increased serum IgG levels than that in the total patient group
(P <0 Æ05 and P <0 Æ01, respectively, Table 1).
Comparison between anti-topo I- and anti-RNAP-positive
patients with dSSc
Although the clinical signiﬁcance of ANA is especially impor-
tant in patients with dSSc, the features found in patients with
anti-topo I or anti-RNAP may be due to the increased dSSc
ratio rather than to the speciﬁc ANA. Therefore, we compared
clinical and laboratory features in patients with dSSc with anti-
topo I or anti-RNAP (Table 2). Patients with anti-RNAP
showed a tendency towards short disease duration compared
with patients with anti-topo I. The ﬁnding that modiﬁed Rod-
nan TSS was similar between the two groups suggests that
patients with anti-RNAP show more rapid progression of skin
Table 2 Clinical and laboratory characteristics of 65 Japanese patients
with the diffuse form of cutaneous systemic sclerosis with anti-
topoisomerase I (anti-topo I) or anti-RNA polymerase I, II and III
(anti-RNAP) antibodies
a
Anti-topo I
(n = 53)
Anti-RNAP
(n = 12)
Age at onset (years),
mean ± SD
43 ± 19 53 ± 16
Sex, female: male
(% of female)
42 : 11 (79) 7 : 5 (58)
Duration (years),
mean ± SD
5Æ2±6 Æ72 Æ6±2 Æ8
Modiﬁed Rodnan TSS,
mean ± SD
18Æ5±9 Æ42 0 Æ7±1 0 Æ6
Clinical features (%)
Pitting scars 62* 25
Contracture of phalanges 68 83
Diffuse pigmentation 62* 92
Organ involvement (%)
Lung
Pulmonary ﬁbrosis 85** 17
Isolated PAH 21 8
Decreased %VC 47* 17
Decreased %DLco 77 58
Oesophagus 71 60
Heart 21 17
Kidney 6 0
Joint 34 50
Muscle 13 17
Laboratory ﬁndings (%), mean ± SD
ESR (mm h
)1) 25 ± 23 17 ± 17
CRP (mg mL
)1)0 Æ6±1 Æ10 Æ3±0 Æ3
IgG (mg mL
)1) 1755 ± 528* 1361 ± 457
aUnless noted otherwise, values are percentages as shown in
Table 1. TSS, total skin thickness score; PAH, pulmonary arterial
hypertension; VC, vital capacity; DLco, diffusing capacity for
carbon monoxide; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein.
*P <0 Æ05 vs. patients with anti-RNAP; **P <0 Æ01 vs. patients
with anti-RNAP.
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RNAP had signiﬁcantly less frequent pitting scars (P <0 Æ05)
and more frequent diffuse pigmentation (P <0 Æ05) compared
with those with anti-topo I. The frequencies of pulmonary
ﬁbrosis and decreased %VC were signiﬁcantly higher in
patients with anti-topo I than in those with anti-RNAP
(P <0 Æ01 and P <0 Æ05, respectively). Serum IgG concentra-
tions in patients with anti-topo I were signiﬁcantly higher
than those in patients with anti-RNAP (P <0 Æ05). Thus,
patients with anti-topo I or anti-RNAP showed some different
features even within the dSSc subgroup.
Survival rates
Overall cumulative rate of survival from the time of diagnosis
of SSc in the 203 patients with SSc was 97% at 5 years and
90% at 10 years. As it has been reported that prognosis in
patients with SSc is associated with the SSc disease subsets, we
assessed the survival rates between the disease subsets. The
cumulative survival rate was signiﬁcantly decreased in the 91
patients with dSSc compared with the 112 patients with lSSc
after 10 years [92% vs. 100% at 5 years (not signiﬁcant) and
77% vs. 98% at 10 years (P <0 Æ01); Fig. 2a]. We then com-
pared the survival rate among four ANA-based subgroups
(Fig. 2b). The survival rate for patients with anti-topo I was
91% at 5 years and 70% at 10 years. This was the worst sur-
vival rate and was signiﬁcantly lower than the rate in the
ACA-positive subgroup (P <0 Æ01). No signiﬁcant differences
were found between ACA-, anti-U1 RNP- and anti-RNAP-posi-
tive patients. Thus, only the patient group with anti-topo I
showed a decreased survival rate during the follow-up period.
Cause of death
Table 3 shows the number of patients with SSc, classiﬁed by
ANA-based subgroup, who died and the causes of their death.
Sixteen of the 203 patients with SSc died during the follow-
up period. Of 11 patients with anti-topo I, six died of res-
piratory failure or infectious pneumonia due to pulmonary
ﬁbrosis and three died of renal involvement which was typical
hypertensive crisis. One anti-topo I-positive patient died of a
malignancy and one of massive alveolar haemorrhage, un-
related to SSc. Only two of the 75 patients with ACA died;
one of them died of right-sided cardiac failure due to isolated
PAH. Of the 12 anti-RNAP-positive patients, one died of car-
diac infarction. One ANA-negative patient died of a continu-
ous bleeding in both the upper and lower gastrointestinal
tract, where the upper lesion was characterized by gastric
antral vascular ectasia. One patient with anti-U1 RNP died
from a malignancy unrelated to SSc. None of the patients with
anti-Th⁄To or anti-U3 RNP died during the follow-up period.
Thus, the major cause of death in patients with SSc was
associated with SSc-related internal organ involvement.
Discussion
In this study of Japanese patients, we compared clinical fea-
tures and prognosis in SSc subgroups with each SSc-related
ANA. Consistent with previous reports, we found strong asso-
ciations between SSc-related ANA and demographic and clini-
cal features as follows: anti-topo I with dSSc and pulmonary
(a) 
(b) 
Fig 2. Cumulative survival rates from the time of diagnosis: (a) 203
Japanese patients with diffuse cutaneous systemic sclerosis (dSSc) and
limited cutaneous SSc (lSSc); (b)161 Japanese patients with SSc with
serum anticentromere, anti-U1 ribonucleoproteins (RNP), anti-DNA
topoisomerase I (topo-I) and anti-RNA polymerase I, II and III
(anti-RNAP) antibodies. Cumulative survival rates were compared
using log-rank tests.
Table 3 Frequency and cause of death in Japanese patients with
systemic sclerosis (SSc), classiﬁed according to the presence of six
SSc-related antinuclear antibodies (ANA) or absence of ANA
Antinuclear
antibody
No. of
patients Cause of death (n)
Anti-DNA
topoisomerase I
11 Pulmonary ﬁbrosis (6),
kidney involvement (3),
malignancy (1),
alveolar haemorrhage (1)
Anticentromere 2 Isolated pulmonary arterial
hypertension (1), unknown (1)
Anti-U1 RNP 1 Malignancy (1)
Anti-RNA
polymerase
I, II, and III
1 Cardiac infarction (1)
Anti-Th ⁄To 0 –
Anti-U3 RNP 0 –
ANA-negative 1 Gastrointestinal involvement (1)
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duration; anti-RNAP with dSSc; anti-Th⁄To with lSSc; and anti-
U3 RNP with dSSc (Table 1 and Refs 29 and 30). However, our
patients generally showed less frequent involvement of isolated
PAH or renal crisis compared with previous reports in other
countries. As a result, patients with ACA or anti-RNAP showed a
remarkably favourable prognosis as did those with anti-U1
RNP. The survival rate was lowest in patients with anti-topo I;
this subgroup frequently developed pulmonary ﬁbrosis, as has
been found in other ethnic groups.
The frequency of ANA in this study was 95%, consistent
with previous studies.
30–32 Anti-topo I was positive in 33% of
203 patients with SSc. This frequency was approximately equal
to previous studies of Japanese patients and relatively higher
than in Caucasian or black African patients.
29–32 Our patients
with SSc had a relatively higher percentage of ACA (38%)
compared with 16–22% of patients in other studies.
29–32 SSc
in overlap syndrome is more common in Japanese compared
with Caucasian or black African patients.
30 However, only 5%
of patients with SSc in our study had anti-U1 RNP. This may
be explained by the fact that patients with SSc in overlap were
excluded from this analysis, and this antibody signiﬁcantly
associates with overlap syndrome.
30 In contrast, frequencies of
anti-Th⁄To, anti-U3 RNP and anti-RNAP were comparable
with those previously reported in Japanese and non-Japanese
patients with SSc.
15,20,29–32 Thus, frequencies of each SSc-
related ANA were generally comparable with those previously
described for Japanese patients with SSc.
Signiﬁcant association of ANA with skin involvement has
been described.
29,30,33 Generally, patients with anti-topo I,
anti-RNAP or anti-U3 RNP tend to present with dSSc and
patients with ACA, anti-U1 RNP or anti-Th⁄To frequently have
lSSc. In our study, 83% of anti-topo I-, 100% of anti-RNAP-
and 80% of anti-U3 RNP-positive patients had dSSc, while
95% of ACA-, 80% of anti-U1 RNP- and 86% of anti-Th⁄
To-positive patients had lSSc (Table 1). Our results were
comparable with those previously seen in Japanese and non-
Japanese patients with SSc.
29,30 Thus, the development of skin
sclerosis is strongly associated with SSc-related ANA and does
not appear to be affected by ethnicity.
Anti-topo I and anti-RNAP are the representative SSc-
speciﬁc antibodies whose clinical presentation is characterized
by dSSc. Both show a diffuse type of skin thickening, but
vasculopathy and pulmonary ﬁbrosis are more frequently
seen in patients with anti-topo I.
29,30 We conﬁrmed previous
ﬁndings that patients with anti-topo I had higher frequencies
of pitting scars and pulmonary ﬁbrosis than did those with
anti-RNAP (Table 2). These results suggest that the patho-
genesis of SSc in patients with anti-topo I might be mediated
by more severe vascular damage compared with those with
anti-RNAP. Another striking ﬁnding was the incidence of
renal involvement, termed renal crisis. Since the occurrence
rate of renal crisis is strongly associated with anti-RNAP,
9,34
the presence of anti-RNAP can guide clinicians to careful
follow-up for the incidence of this complication. Our results
showed that all three patients with renal crisis had anti-topo
I with no incidence in 12 anti-RNAP-positive patients
(Tables 2 and 3). We currently do not have enough data to
account for this discrepancy from previous reports. It may
be due to the difference in genetic background, as the inci-
dence of renal crisis is generally low in Japanese patients
with SSc. Nonetheless, a previous report demonstrated that
43% of patients with anti-RNAP had renal crisis and the
presence of anti-RNAP was associated with both SSc-related
and all-cause mortality in Japanese patients with SSc.
30 As
the previous report was analysed more than 10 years ago, a
possible explanation is the change of environment or treat-
ment during the period. Alternatively, this difference may be
explained by the fact that our study was conducted in der-
matological clinics. Further large, multicentre longitudinal
studies are required to assess the incidence of renal crisis
and the association of renal crisis with ANA in Japanese
patients with SSc.
We conﬁrmed that most patients with ACA are female and
have lSSc, longer disease duration and infrequent internal
organ involvement, except for oesophageal dysfunction. How-
ever, frequencies of vascular damage are different between
Japanese and Caucasian and⁄or black African patients. While
frequencies of pitting scars or ulcers were 42–61% in Cauca-
sian and⁄or black African subjects,
29,35,36 our data showed
that only 17% of ACA-positive patients had pitting scars
(Table 1). Steen reported that isolated PAH was detected in
19% of patients with ACA leading to a decreased survival
rate.
29 In contrast, only 7% of ACA-positive patients in our
study showed isolated PAH and it was not severe except in
one patient who died (Tables 1 and 3, and data not shown).
Thus, the clinical presentation of ACA-positive patients is gen-
erally similar among different ethnic groups, except for the
lower risk or lower severity of vascular involvement in Japa-
nese patients.
Patients with anti-Th⁄To have been reported to have more
subtle cutaneous, vascular and gastrointestinal involvement,
but more often have symptoms commonly seen in dSSc, such
as pulmonary ﬁbrosis and isolated PAH, as well as reduced
survival compared with patients with ACA.
15,29,35 In contrast,
internal organ involvement except for oesophageal dysfunction
is infrequently seen in Japanese patients with anti-Th⁄To.
30 In
this study, patients with anti-Th⁄To had lSSc, with few com-
plications from organ involvement (Table 1). Also, previous
studies have shown that patients with anti-U3 RNP have
severe cutaneous and internal organ involvement.
29,37,38 On
the other hand, lower frequencies and less severe internal
organ involvement were described in Japanese patients with
anti-U3 RNP.
30 In our study, patients with anti-U3 RNP had
dSSc but infrequent internal organ involvement except for
oesophageal dysfunction, similar to those with anti-Th⁄To. It
may be reasonable to conclude that Japanese patients with the
ANA, anti-Th⁄To and anti-U3 RNP, have infrequent or milder
internal organ involvement with better survival compared with
Caucasian and⁄or black African patients with these ANA.
Little has been documented concerning the clinical charac-
teristics of ANA-negative SSc patients. In our study, they had
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and cutaneous involvement. Pulmonary ﬁbrosis and isolated
PAH rarely occurred, but a decrease in %DLco was com-
monly seen. Oesophageal dysfunction occurred in 60% of
this subgroup; however, heart and renal involvement rarely
occurred. Together, these results suggest that patients with
SSc without ANA have infrequent or milder organ involve-
ment. However, it is noteworthy that one patient in this
subgroup died of continuous bleeding in both the upper and
lower gastrointestinal tracts related to SSc. Therefore, it is
important to keep in mind that the absence of ANA in
patients with SSc may not be an indicative marker for spe-
ciﬁc clinical feature but represents the heterogeneity of the
population.
It has been reported that patients with anti-RNAP have the
worst survival rate.
29,30 However, mortality in patients with
anti-RNAP is currently lower than in those with anti-topo I.
29
This is because patients with anti-RNAP have a low risk of suf-
fering pulmonary ﬁbrosis, and renal crisis is now more readily
treated with angiotensin-converting enzyme inhibitors than
pulmonary ﬁbrosis.
39 Our data indicate that patients with anti-
topo I have the worst survival rate of all subgroups and that
the prognosis of other patients with SSc is favourable
(Fig. 2b). Thus, anti-topo I is currently probably the only
marker for poor prognosis in Japanese patients.
In conclusion, grouping patients with SSc according to their
serum ANA may guide the clinician to focus on particular
risks during follow-up in individual patients. However, we
should take into account the ethnic and genetic background as
several clinical features in each SSc-related ANA-based sub-
group appear to vary among populations of different back-
grounds. Moreover, since the number of Japanese patients
reported with anti-RNAP, anti-Th⁄To or anti-U3 RNP is small,
more studies are essential for the better understanding of Japa-
nese patients with SSc with these ANA.
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